Clinical trial
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of…
NCT00133198 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00133198 |
|---|---|
| Title | Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS) |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Restless Legs Syndrome |
| Intervention type | Drug |
| Interventions | Pramipexole |
| Enrollment | 345 |
| Start date | Apr 1, 2004 |
| Primary completion | Feb 1, 2005 |
| Completion | Feb 1, 2005 |
| First posted | Aug 23, 2005 |
| Last update posted | Nov 8, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: